In January 2014, the media reported a study that found men with a history of cardiovascular disease had an increased risk of developing a heart attack in the first 90 days of testosterone therapy.

Those results fly in the face of my own 20-year clinical history of using testosterone. I have found the exact opposite: Bioidentical testosterone therapy, in men or women with low testosterone levels, improved symptoms of cardiovascular disease.

Yet The New York Times picked up the January study and wrote an editorial titled, “Overselling Testosterone, Dangerously.”

How could one study come to a completely different conclusion?

The truth is that the study was so poorly conducted it’s a miracle it was ever published.

The authors compared the incidence of heart attacks in the 90 days following initial prescription of testosterone with the rate in the year prior to that prescription.

There were no blood tests to monitor pre/post testosterone levels or any other type of testing performed.

That is not how I nor anyone else should be prescribing testosterone. In fact, it wasn’t clear if the study subjects even took the testosterone.

Folks, that study was a farce.